CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and begin covering Lilly's new obesity pill Foundayo from June 1 on its standard drug plans. This move balances coverage between Eli Lilly and Novo Nordisk, following CVS's previous deal favoring Novo's Wegovy and dropping Zepbound. Both companies' GLP-1 weight loss drugs will now be co-preferred options on CVS Caremark's standard commercial formulary, potentially benefiting 25 to 30 million Americans. CVS expects this competition to drive 10-15% savings in the weight management drug category and improve patient access to treatments.
Aetna's latest survey shows U.S. healthcare providers' trust in payers increased to a score of 6.1 from 5.4, reflecting improved perceptions of payer reliability and communication. Providers highlight technology's role in reducing administrative task...
CVS Caremark announced a global settlement with the Federal Trade Commission (FTC) resolving all litigation related to rebate practices, pharmacy network contracting, and vertical integration. The agreement ends ongoing investigations and allows CVS ...
